September 8, 2017

Zavante Therapeutics Announces Agreement With NIAID To Assess ZOLYD™ For Lower Respiratory Tract Infections

Oncternal Therapeutics: UCSD cancer clinical trial gets $18.2 million

June 6, 2017

Zavante Therapeutics Presents Positive Results From NIH-Sponsored ZOLYD™ Phase 1 Trial At ASM Microbe 2017 Meeting

May 15, 2017

Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team

May 8, 2017

Retrotope Chairman, Dr. Harry J. Saal, highlights the ideas and concepts behind Retrotope’s technology at TEDxPaloAlto

April 5, 2017

Zavante Therapeutics’ ZOLYD™ Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections

February 22, 2017

Oncternal Closes $18.4 Million Series B Financing

January 19, 2017

Zavante Therapeutics Reports Completion of Patient Treatment in the ZEUS Study of ZTI-01 (fosfomycin for injection) for the Treatment of Complicated Urinary Tract Infections

September 6, 2016

Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company’s Innovative Eye Care Pipeline